Prometheus Biosciences’ comprehensive data set enables target discovery and precision medicine approach in inflammation and immunology
mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients
The blood test market worldwide is today around $75-80 billion
Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases.
Study efficacy measures will include the expression of dystrophin protein and motor function.
Alpenglow has created an end-to-end 3D spatial biology solution including patented high-throughput 3D imaging
The combination will support clients in getting their end-to-end discovery and development programs delivered.
The new team members, Solenn Percelay and Noémie Spinelli, will support the organization’s commitment to excellence in humanized mouse model care and use
Acceptance based on results from the Phase 3 KEYNOTE-859 trial, which showed significant overall survival benefit in these patients with HER2-negative disease, regardless of PD-L1 expression
NGS enables researchers to quickly sequence entire genomes and transcriptomes of organisms.
Subscribe To Our Newsletter & Stay Updated
